Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -712.42% | -14,232.14% | -127.80% | 52.27% | 124.84% |
| Total Depreciation and Amortization | -16.91% | 7.84% | 35.34% | 82.77% | 123.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 557.67% | 638.69% | 561.63% | 607.12% | 38.47% |
| Change in Net Operating Assets | 30.20% | 77.65% | -3.91% | -240.52% | -3,901.28% |
| Cash from Operations | -1,506.55% | -85.25% | 34.24% | 111.44% | 106.63% |
| Capital Expenditure | -2,829.90% | -2,338.27% | 45.92% | 56.53% | 50.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.07% | 143.91% | -411.95% | 146.69% | 139.45% |
| Cash from Investing | -17.81% | 120.12% | -428.72% | 144.07% | 138.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -69.52% | -99.03% | -98.82% | -97.93% | -98.39% |
| Repurchase of Common Stock | 46.18% | 41.74% | 50.15% | 4.06% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 100.00% | 100.00% | 95.22% |
| Cash from Financing | -90.18% | -99.80% | -99.46% | -98.87% | -99.18% |
| Foreign Exchange rate Adjustments | -373.75% | -24.65% | -123.59% | -132.05% | 346.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -185.52% | -327.79% | -195.65% | 1,155.36% | 736.96% |
